US 11,817,219 B2
Systems and methods for assessing cardiovascular disease and treatment effectiveness from adipose tissue
Mark Rabbat, Redwood City, CA (US); Charles Taylor, Atherton, CA (US); Michiel Schaap, Oegstgeest (NL); Timothy Fonte, San Francisco, CA (US); and Leo Grady, Darien, CT (US)
Assigned to HeartFlow, Inc., Mountain View, CA (US)
Filed by HeartFlow, Inc., Redwood City, CA (US)
Filed on Sep. 7, 2022, as Appl. No. 17/930,090.
Application 17/930,090 is a continuation of application No. 16/654,698, filed on Oct. 16, 2019, granted, now 11,462,329.
Claims priority of provisional application 62/746,972, filed on Oct. 17, 2018.
Prior Publication US 2023/0005622 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. G16H 50/30 (2018.01); G16H 50/50 (2018.01); G16H 30/20 (2018.01); A61B 5/02 (2006.01); A61B 5/00 (2006.01)
CPC G16H 50/30 (2018.01) [A61B 5/02007 (2013.01); A61B 5/4848 (2013.01); A61B 5/7278 (2013.01); G16H 30/20 (2018.01); G16H 50/50 (2018.01)] 17 Claims
OG exemplary drawing
 
1. A computer-implemented method for determining a blood-flow metric based on adipose tissue, comprising:
determining a patient-specific model of blood flow through anatomy of a patient, the patient-specific model of blood flow including boundary conditions at inflow and outflow boundaries of the anatomy;
determining a patient-specific inflammation index of the anatomy of the patient, the patient-specific inflammation index being based on adipose tissue identified within a predetermined distance of the anatomy, wherein determining the patient-specific inflammation index includes:
obtaining patient-specific medical imaging of the anatomy;
identifying adipose tissue in the patient-specific medical imaging;
determining a quantification of the identified adipose tissue that is weighted based on distance between the identified adipose tissue and a region of interest; and
determining the patient-specific inflammation index based on the quantification;
modifying at least one of the boundary conditions of the patient-specific model of blood flow based on the patient-specific inflammation index; and
determining at least one patient-specific blood-flow metric using the patient-specific model of blood flow with the at least one modified boundary condition.